Monoclonal antibody-assisted structure-function analysis of the carbohydrate recognition domain of surfactant protein D by Hartshorn, Kevan L et al.
Monoclonal antibody-assisted structure-function analysis of the carbohydrate
recognition domain of surfactant protein D
Kevan L. Hartshorn,1 Mitchell R. White,1 Michael Rynkiewicz,2 Grith Sorensen,3 Uffe Holmskov,3
James Head,2 and Erika C. Crouch4
Departments of 1Medicine and 2Biophysics, Boston University School of Medicine, Boston, Massachusetts; 3Department
of Immunology and Microbiology and Medical Biotechnology Center, Institute of Medical Biology, University of Southern
Denmark, Odense, Denmark; and 4Department of Pathology and Immunology, Washington University School of Medicine,
St. Louis, Missouri
Submitted 25 March 2010; accepted in final form 28 June 2010
Hartshorn KL, White MR, Rynkiewicz M, Sorensen G, Holm-
skov U, Head J, Crouch EC. Monoclonal antibody-assisted structure-
function analysis of the carbohydrate recognition domain of surfactant pro-
tein D. Am J Physiol Lung Cell Mol Physiol 299: L384–L392, 2010. First
published July 2, 2010; doi:10.1152/ajplung.00096.2010.—Surfactant pro-
tein D (SP-D) plays important roles in host defense against a variety
of pathogens including influenza A virus (IAV). Ligand binding by
SP-D is mediated by the trimeric neck and carbohydrate recognition
domain (NCRD). We used monoclonal antibodies (mAbs) against
human SP-D and a panel of mutant collectin NCRD constructs to
identify functionally and structurally important epitopes. The ability
of SP-D to bind to IAV and mannan involved partially overlapping
binding sites that are distinct from those involved in binding to the
glycoprotein-340 (gp-340) scavenger receptor protein. A species-
specific motif (D324,D325,R343), which has been implicated in the
specific binding of several ligands, contributes to recognition by
mAbs that block antiviral or mannan binding activity. D325, in
particular, is involved in the epitopes of these blocking mAbs. Con-
versely, the interspecies substitution of arginine for Lys343 in the rat
NCRD (rK343R) conferred binding to two of the mAbs. The single
site substitution of alanine for R349 or E347 resulted in highly
selective alterations in mAb binding and caused decreased antiviral
activity. Mutations at Glu333 (E333A), Trp340 (W340F), and Phe335
(F335A), which abrogated antiviral activity, were associated with
decreased binding to multiple blocking mAbs, consistent with critical
structural roles. More conservative substitutions at 335, which showed
a significant increase in neutralization activity, caused selective loss of
binding to one mAb. The analysis reveals, for the first time, an
extended binding site for IAV; calcium-dependent antiviral activity
involves residues flanking the primary carbohydrate binding site as
well as more remote residues displayed on the carbohydrate recogni-
tion domain surface.
influenza virus; collectins
SURFACTANT PROTEIN D (SP-D) is present in lung lining fluids and
a variety of other mucosal locations where it participates in
binding and inhibiting a wide range of infectious organisms,
including bacteria, fungi, and viruses (27). SP-D is a member
of the collectin family of innate defense proteins that contain a
structurally important collagen domain and trimeric neck and
carbohydrate recognition domains (termed NCRDs from here
on) that are involved in calcium-dependent binding to specific
carbohydrate epitopes on microorganisms or mammalian cells.
We and others have studied the interactions of SP-D with
influenza A viruses (IAVs) (11, 14, 16, 20, 21). Mice lacking
SP-D due to gene deletion exhibit more severe illness, higher
viral loads, and greater inflammatory response when infected
with human strains of IAV. Inhibition of IAV by SP-D is
determined mainly by the presence of high mannose oligosac-
charides on the viral hemagglutinin (HA) (13, 20, 23). SP-D
also plays an important role in inhibiting inflammatory re-
sponses triggered by LPS and bacteria (15, 19, 27). Finally,
SP-D plays an important role in maintenance of surfactant lipid
homeostasis in vivo (1).
Monoclonal antibodies (mAbs) directed against the NCRD
of SP-D have proved useful in determining functionally im-
portant regions of the protein and demonstrating the role of
cross-linking of NCRD trimers in antiviral activity (12, 22).
We (22) have previously reported that a panel of mAbs
directed against the NCRD of SP-D can be grouped into ones
that inhibit antiviral activity of SP-D against IAV and others
that do not. The antibodies that do not inhibit viral binding or
antiviral activity include two that are directed against the neck
domain of SP-D (245-01 and 245-02). The latter mAb recog-
nizes not only the neck, but also some portion of the carbohy-
drate recognition domain (CRD) because it retains the ability to
bind to a preparation containing only the CRD of SP-D
(whereas 245-01 loses binding altogether to this preparation).
Two other mAbs that do not block antiviral activity of full-
length SP-D strongly increase the antiviral activity of NCRD
trimer preparations of SP-D by cross-linking and enhancing
binding of the NCRD to the virus. Finally, one other nonblock-
ing antibody (246-06) does not block or increase activity of
full-length SP-D or NCRDs.
In this paper, we more fully characterize the effect of the
various antibodies on antiviral activity as well as binding to
mannan and scavenger receptor protein glycoprotein-340 (gp-
340). We also characterize epitopes of the mAbs by comparing
their binding with a panel of similarly prepared wild-type and
mutant NCRD trimers derived from SP-D. Finally, we compare
the effect of specific mutations of the NCRD on antiviral
activity. Certain NCRD sites are shown to be critical in
modulating antiviral activities of SP-D and antibody recogni-
tion. Some combinations of mutations are shown to restore
epitopes of human SP-D lost in rodent SP-Ds or in single site
mutants of human SP-D. Other mutations are shown to cause
marked structural alterations based on loss of binding to
multiple mAbs. Through these studies, we demonstrate that
residues adjacent to the lectin site, as well as more distant
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residues on the CRD surface, make up an extended binding
region for viral oligosaccharides.
MATERIALS AND METHODS
Virus preparation. IAV was grown in the chorioallantoic fluid of
10-day-old chicken eggs and purified on a discontinuous sucrose
gradient as previously described (10). The virus was dialyzed against
PBS to remove sucrose, aliquoted, and stored at 80°C until needed.
Philippines 82/H3N2 (Phil82) strain was kindly provided by Dr. E.
Margot Anders (Univ. of Melbourne, Melbourne, Australia) (7).
Postthawing, the viral stocks contained 5  108 plaque-forming
units/ml.
Collectin preparations. Dodecamers of wild-type recombinant hu-
man SP-D were used as a control and were expressed in CHO cells
and purified as previously described (8). Trimeric wild-type and
mutant NCRD fusion proteins were expressed in Escherichia coli (5,
6). All fusion proteins contain an identical NH2-terminal His tag, used
for initial purification, and an internal S protein binding site permits
detection using S protein-horseradish peroxidase (HRP) as previously
described (5). Wild-type trimeric human and rat NCRDs are desig-
nated hNCRD and rNCRD, respectively. Mutant NCRDs are identi-
fied by the species of origin (h or r) followed by the position(s) of
substitution in the mature proteins.
NCRD fusion proteins were extracted from inclusion bodies, re-
folded and oligomerized by dialysis, and purified by nickel affinity
chromatography, and the predominant trimeric species was isolated by
gel filtration chromatography (5, 6). All NCRDs migrated as a single
major band of the appropriate size on SDS-PAGE with the expected
decrease in mobility on reduction, consistent with the formation of
normal intrachain disulfide bonds (data not shown). Except where
indicated, mutant NCRDs showed retention of some or all of the
calcium-dependent carbohydrate binding activities of the native pro-
tein. The endotoxin level of all SP-D preparations was approximately
0.1–0.5 EU/ml (Limulus Lysate Assay; Cambrex, Walkersville, MD).
mAbs. mAbs 245-01, 245-02, and 246-02 through 246-08 were
raised against SP-D by inoculating mice with 10 g/ml human SP-D
as previously described (17).
Binding of mAbs to SP-D or NCRD. SP-D preparations were
diluted in coating buffer to a concentration of 2 g/ml and coated on
ELISA plates overnight, followed by washing and addition of mAbs.
The final concentration of mAbs used for the ELISA assay was 1
g/ml. The binding assays were carried out in PBS containing
calcium and magnesium. Bound mAbs were detected with HRP-
conjugated donkey anti-mouse antibodies labeled followed by
3,3=,5,5=-tetramethylbenzidine (TMB) peroxidase. Optical density at
450-nm values were measured on a POLARstar OPTIMA plate reader
(BMG Labtech, Durham, NC).
Binding of NCRDs to IAV. Binding of NCRD fusion proteins to
IAV was measured as previously described (5) by use of the S protein
binding site on the fusion tag of the NCRD. In brief, IAV (Phil82
strain) was coated onto the surface of ELISA plates, and, following
washing, NCRDs were added. After incubation and washing, S
protein-HRP was added, and peroxidase activity was measured.
HA inhibition assay. The studies involving blood cells from vol-
unteer donors were approved by the Boston University School of
Medicine institutional review board. Hemagglutination (HA) inhibi-
tion was measured by serially diluting collectins or other host defense
protein preparations in round-bottom 96-well plates (Serocluster U-
Vinyl plates; Costar, Cambridge, MA) using PBS containing calcium
and magnesium as a diluent (11). After adding 25 l of IAV, giving
a final concentration of 40 HA U/ml or 4 HA U/well, the IAV/protein
mixture was incubated for 15 min at room temperature, followed by
addition of 50 l of a type O human erythrocyte suspension. The
minimum concentration of protein required to fully inhibit the HA
activity of the viral suspension was determined by noting the highest
dilution of protein that still inhibited HA. Inhibition of HA activity in
a given well is demonstrated by absence of formation of an erythro-
cyte pellet. If no inhibition of HA activity was observed at the highest
protein concentration used, then the value is expressed as greater than
the maximal protein concentration.
Fluorescent focus assay of IAV infectivity. Madin-Darby canine
kidney (MDCK) cell monolayers were prepared in 96-well plates and
grown to confluence. These layers were then infected with diluted
IAV preparations for 45 min at 37°C in PBS and tested for presence
of IAV-infected cells after 7 h using a mAb directed against the
influenza A viral nucleoprotein (provided by Dr. Nancy Cox, Centers
for Disease Control and Prevention, Atlanta, GA) as previously
described (9). IAV was preincubated for 30 min at 37°C with
collectins or control buffer, followed by addition of these viral
samples to the MDCK cells. Where indicated, collectins were first
incubated with mAbs before addition to IAV.
Statistics. Statistical comparisons were made using Student’s
paired, two-tailed t-test or ANOVA with post hoc test (Tukey).
ANOVA was used for multiple comparisons with a single control.
RESULTS
Comparison of effects of mAbs on the ability of wild-type
human SP-D to bind to mannan, IAV, or gp-340. As shown in
Fig. 1, mAbs 246-02, 246-03, and 246-07 strongly inhibited
binding to mannan. We (22) have reported that these mAbs
also inhibit antiviral activity of SP-D. mAbs 246-05 and
246-06 inhibited binding to mannan at 10 but not 1 g/ml.
mAbs 245-01 and 245-02 that recognize the neck region of
SP-D did not inhibit binding to mannan, and 246-04 and
246-08 caused only slight inhibition (not dose-related for
246-08). Overall, these results indicate a correlation between
Fig. 1. Effect of monoclonal antibodies (mAbs) on binding of surfactant
protein D (SP-D) dodecamers to mannan or glycoprotein-340 (gp-340). Man-
nan (A) or gp-340 (B) were bound to ELISA plates. Human SP-D dodecamers
were preincubated with the indicated mAbs at either 1 or 10 g/ml as
indicated. The results are means  SE of 2 experiments. Additional experi-
ments (data not shown) were done in which the assay was carried out in
EDTA-containing buffer, which prevented binding of SP-D to either mannan
or gp-340. Preincubation of SP-D with maltose prevented binding to mannan
but not to gp-340 (data not shown). *A specific concentration of mAb caused
significant reduction of SP-D binding to mannan or gp-340 (P  0.05).
L385STRUCTURE-FUNCTION ANALYSIS OF SP-D
AJP-Lung Cell Mol Physiol • VOL 299 • SEPTEMBER 2010 • www.ajplung.org
 by 10.220.33.3 on January 15, 2017
http://ajplung.physiology.org/
D
ow
nloaded from
 
ability of mAbs to inhibit binding to mannan with their inhi-
bition of antiviral activities of SP-D: mAbs 246-02, 246-03,
and 246-07 strongly inhibit both, whereas 246-04 and 246-08
and the neck mAbs do not substantially inhibit either activity.
However, there were two discrepancies. First, 246-05, which
strongly inhibits antiviral activity, only inhibited mannan bind-
ing at the higher antibody concentration. Second, 246-06 did
not inhibit antiviral activity but inhibited binding to mannan at
the higher antibody concentration.
The ability of mAbs to inhibit binding to gp-340 did not
consistently correlate with these other properties. For instance,
as reported (26), mAb 245-01 inhibits binding to gp-340
(without inhibiting antiviral activity or binding to mannan).
The 246-07 mAb completely inhibited binding to mannan at
low concentrations but inhibited binding to gp-340 only par-
tially and at the higher mAb concentration. Two antibodies that
strongly inhibit antiviral activity and mannan binding also
inhibit binding to gp-340 (246-02 and 246-03). The higher
concentration of mAb 246-06 caused stronger inhibition of
binding to mannan than to gp-340. Finally, 246-04, 246-08,
and 245-02 do not inhibit binding to any of the ligands. Note
that preincubation of SP-D with maltose did not alter its
binding to gp-340 or recognition by the mAbs of SP-D bound
to gp-340 (data not shown). In contrast, preincubation elimi-
nated binding of SP-D to mannan, and EDTA abolished bind-
ing of SP-D to either mannan or gp-340 (data not shown).
Hence, binding of SP-D to gp-340 is calcium-dependent but
not altered by occupancy of the lectin site with maltose.
Overall, these results indicate that the mechanisms of binding
to mannan and IAV are similar but not identical and that SP-D
has distinct mechanisms of attachment to gp-340.
Contributions of a species-specific motif to antibody
binding. Rat SP-D NCRD resembles human SP-D NCRD in its
poor binding to IAV but has greater apparent affinity for
phosphatidylinositol (PI) and LPS (24). These differences are
in part attributable to differences in hydrophilic residues that
flank calcium at the primary carbohydrate binding site. SP-Ds
of most species have N324,N325 and K343, whereas human
SP-D is characterized by D324,D325 and R343. We have
previously shown that the difference at 325 contributes to
preferential recognition of N-acetyl-mannosamine by human
SP-D (6) and that the residue at 343 contributes to enhanced
recognition of LPS and PI by rat and mouse NCRDs (4, 24).
Although human SP-D was used to generate the panel of
mouse mAbs, certain mAbs can bind to rodent NCRDs (22).
For instance, the NCRD of rat SP-D binds to mAb 246-03 and,
to a lesser degree, to 246-08. Accordingly, we used combina-
torial, reciprocal mutagenesis to examine the contributions of
the distinctive 324,325,343 motif to differences in antibody
binding.
A rat triple mutant (rN324DN325DK343R, designated
DDR) and rK343R, which were designed to resemble the
human protein, showed a marked increase in binding to mAbs
246-05 and 246-06 (Fig. 2A). By contrast, rN324DN325D,
(designated DD) showed no increase in binding to these mAbs
and lost affinity for 246-03. These findings confirm our prior
report that R343 in human SP-D is involved in binding to
246-05 (2). Furthermore, they demonstrate that R343 is in-
volved in binding to 246-06 and suggest that N324 and N325
somehow contribute to cross-reactivity of rodent proteins with
246-03.
We also took the reverse approach and studied the ability of
the mAbs to bind to human NCRDs with interspecies substi-
tutions at the 324, 325, and/or 343 positions. The hD324N
mutation did not affect binding to any of the mAbs (Fig. 2B);
however, hD325N decreased binding to all of the blocking
mAbs (246-03, 246-05, 246-06, and 246-07) except for 246-02.
A double mutant (hD324ND325N, designated hNN) caused
some decrease in binding to 246-02 but was otherwise similar
to hD325N. However, a triple mutant with the complete rodent
motif (hD324ND325NR343K, designated hNNK) caused
more profound suppression of binding to 246-05 and some
suppression of binding to 246-02. We (2) have previously
reported that the single mutant, R343K, has reduced binding to
246-05. These observations further confirm the importance of
R343 in binding to mAb 246-05. More broadly, the results
Fig. 2. Binding of mAbs to trimeric neck and carbohydrate recognition domains (NCRDs) derived from rat or human SP-D. The indicated NCRD preparations derived
from rat SP-D (A) or human SP-D (B) were coated onto ELISA plates, and binding of mAbs were tested as described. Results are means  SE of 3 experiments and
are expressed as percentage of binding to wild-type human NCRD (hNCRD) control. In A, mAbs 246-05 and 246-06 showed significantly greater binding to rat triple
mutant (rN324DN325DK343R; rDDR) and rK343R than to wild-type rat NCRD (rNCRD; #P  0.05). mAb 246-03 had significantly reduced binding to
rN324DN325D (rDD). In B, hD325N had significantly decreased binding to 246-03, 246-05, 246-06, and 246-07; human double mutant (hD324ND325N; hNN)
had reduced binding to 246-02, 246-03, 246-05, and 246-07; human triple mutant with complete rodent motif (hD324ND325NR343K; hNNK) had reduced binding
to 246-02, 246-03, 246-05, 246-06, and 246-07. *Significantly reduced mAb binding (P  0.05).
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indicate the importance of D325 in the antigenic structure of
hNCRD and confirm its importance in binding to a variety of
key ligands (6). D325 contributes to a distinctive ridge on the
outer edge of the binding surface of hNCRD. Note that none of
these changes affected binding to 246-04, 246-08, or the neck
mAbs (data not shown).
Figure 3A shows the effects of mutant versions of rat and
human SP-D NCRDs on binding to IAV as assessed by ELISA.
All of these NCRDs contain S protein binding sites on the NH2
terminus to allow for uniform detection of bound NCRD using
S protein-HRP conjugates. Results obtained with hR343V and
hR343A are shown for comparison. Whereas these mutants
had markedly increased viral binding (as previously reported),
hR343K, rDDR, hNN, and hNNK did not.
Figure 3B shows effects of these mutations on viral neutral-
izing activity. hNCRD had minimal neutralizing activity, as
previously reported (6), and none of the mutants discussed in
this section had increased activity. Again, hR343V and
hR343A, which have strong activity, were tested in parallel as
positive controls. Interestingly, hNNK caused significant in-
crease in viral infectivity.
To amplify subtle differences in antiviral activity, we incu-
bated NCRDs with S protein-HRP conjugates, which effec-
tively cross-link the protein and increase binding via increased
cooperative interactions among trimeric NCRDs (25). Figure
3C demonstrates that rDDR and hR343K had similar activity to
hNCRD or rNCRD after cross-linking; however, hNNK lacked
activity. Hence, hNNK lost antiviral activity compared with
wild-type hNCRD.
Contributions of Phe335 to antibody binding. In recent
studies, we (3) have shown that specific residues that are
relatively remote from the primary carbohydrate binding site,
but that are exposed at the putative ligand binding interface,
contribute to the recognition of specific oligosaccharides. In
particular, we have shown that the aromatic ring of Phe335 can
participate in stacking interactions with ligand and that certain
amino acid substitutions can alter interactions with specific
ligands.
hF335A appears inactive as a lectin (3) and lacked neutral-
izing activity (and even increased viral infectivity like hNNK;
Fig. 4A). In contrast, the neutralizing activity of hF335Y and
hF335W was significantly greater than that of either the wild-
type hNCRD or hF335A. Furthermore, hF335Y inhibited HA
activity after cross-linking with S protein-HRP (mean HA
inhibitory concentration: 2,290  100 ng/ml; n  3), but
hF335A did not. hF335A also showed greatly reduced binding
to blocking antibodies 246-03, 246-05, and 246-07; there was
partial inhibition of binding to 246-06 (Fig. 4B). By contrast,
hF335Y or hF335W, which show normal or enhanced binding
to mannan or maltotriose, respectively (3), showed much more
selective changes in antibody reactivity (i.e., significantly re-
duced binding of mAb 246-07 only).
Contributions of other hydrophilic residues at the ligand
binding surface. We also modified selected, highly exposed
charged residues displayed at the ligand binding surface of the
CRD. The side chains of R349, E333, and E347 of the human
NCRD participate in a distinctive network of hydrogen bonds,
which also involves R343 (Fig. 5). In addition, E333 coordi-
nates with Asn341, which, in turn, participates in calcium
coordination at the primary carbohydrate binding site (3). The
functional consequences of mutations at these sites are the
subject of active investigation; however, only E333 appears
Fig. 3. Binding, neutralization, and hemagglutination (HA) inhibition of influenza A virus (IAV) by wild-type and mutant NCRDs. A: the Philippines 82/H3N2
(Phil82) strain of IAV was coated onto ELISA plates, and binding of the indicated NCRDs was tested using S protein-horseradish peroxidase (HRP) for detection.
Results are means  SE of 3 experiments. Binding of R343V or R343A was significantly greater than wild-type hNCRD (**P  0.01). OD450, optical density
at 450-nm values. B: viral neutralization was tested by preincubating IAV with 20 g/ml indicated NCRDs followed by measurement of infectious virus by the
fluorescent focus assay (see MATERIALS AND METHODS). Results are means  SE of 3 or more experiments and are expressed as percentage of control infectious
foci (control being untreated virus). hR343V and hR343A caused significant inhibition of viral infectivity (*), NNK caused significant increase in viral infectivity
(#), and the other NCRDs did not significantly alter infectivity compared with untreated virus (P 0.05 vs. control). C: HA inhibition by the NCRDs alone (white
bars) or after preincubation of the NCRDs with S protein-HRP (black bars), which causes cross-linking of the NCRDs. hR343V caused significantly greater HA
inhibition than hNCRD with and without S protein-HRP (*); however, hNNK caused significantly less HA inhibition than hNCRD (#) (both P  0.05). Conc.,
concentration.
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generally required for lectin activity. The hR349A mutation
selectively decreased binding of 246-05, 246-06, and 246-07
(Fig. 6A). Note the proximity of R349 to R343, mutations of
which also reduce binding to mAbs 246-05 and 246-06. Hu-
man E333A caused more extensive structural alterations in that
it greatly reduced binding of 246-03, 246-05, 246-06, and
246-07. Nevertheless, it did not alter binding to 246-04, 246-
08, or the neck mAbs (data not shown). The hE347A substi-
tution caused a modest decrease in binding of 246-07 only.
Based on crystallographic analysis, lysine 348 (K348) also
extends into the ligand binding interface. Modification of this
lysine to asparagine (hK348Q, as found in rat and mouse) or
alanine (hK348A) did not cause obvious effects on binding to
mannan or IAV (data not shown). It also did not affect binding
to any of the mAbs (Fig. 6A).
Hence, mutating some of the exposed charged residues on
hNCRD had greater effects on the structure than mutating
others. In general, those in which structure was altered more
substantially also showed greater loss in antiviral activity. As
shown in Fig. 6B, hK348A and hK348Q had activity similar to
(or greater than) wild-type hNCRD (compare neutralization
and HA inhibition results with Fig. 3). Human R349A and
E347A showed a significant reduction in activity in the HA
inhibition assay and did not cause viral neutralization. hE333A
entirely lacked HA inhibiting activity, and, like hNNK,
hE333A significantly increased viral infectivity.
Contributions of residues coordinating with calcium. Con-
served residues coordinating with calcium at the primary car-
bohydrate binding site have not yet been systematically exam-
ined by mutagenesis. This is largely because of their inevitable
effects on calcium affinity, with predictable alterations in
ligand binding. However, hE321K, which was identified in
genomic sequence, has been examined in conjunction with
other studies. As anticipated, hE321K lacks binding activity in
all solid-phase carbohydrate binding assays (data not shown).
Notably, this mutation caused loss of binding to 246-03 and
246-07 and reduction in binding of 246-05, again without
changing binding of 246-02, 246-04, 246-08, or the neck mAbs
(245-01 and 245-02; Fig. 7A and data not shown). We (22)
have previously reported that the E321K mutation abolishes
HA inhibitory activity even after cross-linking.
Modification of the conserved CRD core. Tryptophan 340
(W340) is part of the highly conserved C-type lectin motif and
plays critical structural roles, deep to the primary carbohydrate
binding site. Even the comparatively conservative W340F
substitution markedly altered binding to all of the mAbs except
246-02, including in this case 246-04 (Fig. 7A). W340F was
also the only mutant version of hNCRD that we tested that
nearly entirely lacked binding to mAb 246-08 (binding5% of
Fig. 4. Viral neutralization by, and mAb binding to, NCRDs with substitutions at F335. Three mutant NCRD with substitutions for F335 were tested for their
independent neutralizing activity in A (assay as described in Fig. 3). Wild-type hNCRD did not alter viral infectivity, but the F335Y and F335W mutants did
(#significantly increased viral infectivity compared with control; *significantly reduced viral infectivity compared with control; P  0.05; n  4). The F335A
mutant actually resulted in a significantly increased viral titer compared with control buffer or wild-type hNCRD (P  0.02; n  4). Binding of the indicated
mAbs to the F335 mutants is shown in B, and results are shown as percentage of control binding to wild-type hNCRD. The F335Y and F335W mutants showed
a significant reduction in binding of mAb 246-07 only, whereas, mAbs 246-03, 246-05, 246-06, and 246-07 all had significantly reduced binding to F335A
(*significantly reduced mAb binding; P  0.04; n  4).
Fig. 5. Hydrogen bonding among charged surface residues on hNCRD. A
network of hydrogen bonds involving charged residues on the surface of the
wild-type hNCRD are shown.
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control; n 3). Not surprisingly, the W340F mutation resulted
in decreased mannan binding and loss of antiviral activity; in
fact, like the E333A, NNK, and F335A mutations, W340F
showed significantly increased viral infectivity (Fig. 7B).
W340F also had no HA inhibitory activity after cross-linking
with S protein-HRP (data not shown).
Modification of conserved residues remote from the ligand
binding surface. As noted previously, 246-08 and 246-04 have
binding properties that suggest interactions with the neck or the
lateral or “back” surfaces of the human CRD. In particular,
these antibodies can enhance viral interactions via cross-link-
ing of NCRDs (22). Although systematic mutational analysis
of these regions has not been performed, we have recently
examined the effects of mutations of tyrosines 228, 306, and
314; all of these residues are highly conserved in SP-D and are
at least partially exposed to solvent. Through combinatorial
substitution of phenylalanine for tyrosine, we (18) have shown
that hY314 is a preferred site for nitration of SP-D and hY228
(in neck domain) is a preferred site for peroxynitrite-dependent
cross-linking of NCRDs. Nevertheless, even a triple mutation
Fig. 6. hNCRD mutants with removed charged
residues: mAb binding, viral neutralization, and
HA inhibition. A: experiments were performed
as in Fig. 2. Note that all mAbs bound to the
hK348Q or hK348A mutants to the same extent
as to wild-type hNCRD. The hE347A mutant
only showed slight reduction in binding to
246-07 mAb. The hR349A mutant showed sig-
nificantly reduced binding to mAbs 246-05,
246-06, and 246-07. hE333A showed reduction
of binding to these same mAbs but also to
246-03. Results are means  SE of 4 experi-
ments. *Instances of significantly reduced mAb
binding (P  0.05). B: neutralizing activity of
indicated hNCRD mutants was tested as in Fig.
3 (n  4). The hK348Q and hK348A mutants
caused slight but statistically significant reduc-
tion in viral titers (*P  0.05 for either); how-
ever, hE347A and hR349A did not. hE333A
actually increased viral infectivity compared
with control buffer (#P  0.004). C: HA inhi-
bition after cross-linking with S protein-HRP
was tested as in Fig. 3 (n  4). The hK348A
mutant had similar activity to wild-type hNCRD
on this assay, whereas activity of hE347A and
R349A was reduced (#P  0.05 vs. hNCRD),
and hE333A had no activity (#P  0.05 vs.
hNCRD).
Fig. 7. Binding of mAbs to hW340F and
hE321K and viral neutralization by mutant
NCRDs with substituted tryptophans or ty-
rosines. A: hW340F showed markedly reduced
binding to all mAbs tested, and hE321K
showed reduced binding to 246-03, 246-05,
246-06, and 246-07. *Significant reduction in
mAb binding to the NCRD. B: hW340F sig-
nificantly increased viral infectivity (#P 
0.05 vs. control buffer or hNCRD). Neutraliz-
ing activity of hY314F, hY306F, and hW317F
was not significantly different than wild-type
hNCRD control (i.e., no significant reduction
in viral infectivity).
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did not significantly interfere with lectin activity. Notably,
hY228F, hY306F, hY314F, and hW317F mutations (alone or
in combination) did not change binding to any of the mAbs,
including 246-04 and 246-08 (data not shown, Table 1). In
contrast to the hE321K and hW340F mutants, hY306F,
hY314F, and hW317F retained some neutralizing activity as
shown in Fig. 7B. Human Y306F also inhibited HA activity
after cross-linking with S protein-HRP (mean HA inhibitory
concentration: 2,400  700 ng/ml; n  3).
DISCUSSION
mAbs facilitate the identification of ligand binding sites. Our
results establish that sites for binding of gp-340 and mannan
are distinct and that the mannan binding region overlaps with
that for binding to IAV. In general, mAbs that block binding to
IAV or mannan have epitopes that include hydrophilic residues
that reside on the ridges that flank the primary carbohydrate
binding site. mAbs binding to the neck or those that bind
neither to the ligand binding surface nor the neck (246-04 and
246-08) do not block antiviral activity and in some cases
enhance it.
We cannot precisely localize the site(s) of binding for
gp-340; however, it is “near” the lectin site because mAbs
246-02 and 246-03, which recognize residues flanking this site
and block binding to mannan or IAV, strongly inhibit binding
to gp-340. The finding that 245-01 inhibits binding of gp-340
suggests that gp-340 also interacts with more distant sites.
Notably, binding to gp-340 is calcium-dependent but not sen-
sitive to competing maltose, suggesting that it recognizes a
calcium-dependent conformation of the NCRD. In addition,
porcine SP-D has a glycan on the lateral surface of the NCRD
that inhibits binding to gp-340 (26). In sum, these findings
support the concept that the binding site for gp-340 is distinct
from the lectin site. We speculate that the calcium dependence
reflects structural roles of the secondary calcium ions, which
stabilize loop structures at the lateral surface of the CRD, near
the glycan attachment in porcine SP-D.
mAbs identify key antigenic sites on the NCRD. Table 1
summarizes our current findings regarding the functional ac-
tivities and mAb binding profile of the panel of NCRDs used
in this paper. Our studies indicate that D325, which is the most
prominent residue on one of the ridges alongside the primary
carbohydrate binding site of SP-D, is both a key epitope and
critical for the ligand recognition properties of SP-D. Substi-
tutions at this site not only change saccharide binding selec-
tivity (6), but also interfere with binding to most of the
blocking mAbs we tested. It is of interest that rat SP-D NCRD
does not bind to most blocking mAb, whereas binding to one
of the nonblocking mAbs (246-08) is relatively conserved.
R343 defines the other ridge adjacent to the lectin site and also
contributes to antibody binding but is apparently less important
than D325; substitution of hydrophobic residues at 343
Table 1. Summary of mannan binding and antiviral activity of wild-type and mutant NCRDs and of binding of monoclonals
to the NCRDs
Trimeric NCRD Mannan Binding
Antiviral
Activity 246-02 246-03 246-04 246-05 246-06 246-07 246-08
hNCRD Binds* None† Binds‡ Binds Binds Binds Binds Binds Binds
hD324ND325N (NN) Increased Same Binds Binds Binds Decreased Binds — Binds
hD324N (N324) Binds Binds Binds Binds Binds Binds Binds Binds
hD325N (N325) Increased Binds Binds Binds — Decreased — Binds
hR343K Decreased Same Binds Binds Binds Decreased Binds Binds
hD324ND325NR343K (NNK) Binds — Decreased Decreased Binds — Decreased — Binds
rNCRD Binds Same — Binds — — — — Binds
rN324DN325D (DD) Decreased Same — Decreased — — — —
rK343R (R343) Increased Same — Decreased — Binds Binds —
rN324DN325DK343R (DDR) Binds Same — Binds — Binds Binds — Binds
Phe335 mutants
hF335A — — Binds Decreased Binds Decreased Binds — Binds
hF335Y Increased Increased Binds Binds Binds Binds Binds — Binds
hF335W Binds Increased Binds Binds Binds Binds Binds — Binds
Charge network mutants
hE333A — — Binds Decreased Binds — Decreased — Binds
hE347A Binds Same Binds Binds Binds Binds Binds Binds Binds
hK348A Binds Increased Binds Binds Binds Binds Binds Binds Binds
hK348Q Binds Same Binds Binds Binds Binds Binds Binds Binds
hR349A Decreased Decreased Binds Binds Binds — Decreased Decreased Binds
Other mutants
hE321K — — Binds Decreased Binds Decreased Binds — Binds
hW340F Decreased — Binds Decreased — Decreased — — —
hY228FY306FY314F Binds Same Binds Binds Binds Binds Binds Binds Binds
*Binding of trimeric neck and carbohydrate recognition domains (NCRDs) to mannan expressed relative to binding of the wild-type human NCRD (hNCRD).
Mannan binding results are summarized from prior publications (2-6, 21) or unpublished data. †Antiviral activity was assessed by direct neutralizing activity or
hemagglutinin (HA)-inhibitory activity (after cross-linking of the NCRDs with S protein-horseradish peroxidase). Without cross-linking, the wild-type hNCRD
had no neutralizing or HA-inhibiting activity, but it did have HA-inhibitory activity after cross-linking. The other NCRDs are compared with wild-type hNCRD
(see Figs. 3, 4, 6, and 7 for specific results of antiviral activity assays). ‡Monoclonal antibody (mAb) binding results are summarized from Figs. 2, 4, 6, and 7.
An antibody “binds” if binding is	50% of that observed for the hNCRD. Binding is described as “decreased” if binding is50%. Binding (or antiviral activity)
of 20% of control was not considered significant and is indicated by a minus sign. Where spaces are left blank, no value was determined. IAV, influenza A
virus; rNCRD, wild-type trimeric rat NCRD; charge network mutants, hNCRD mutants with removed charged residues.
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strongly affected binding of one antibody, 246-05, and affected
to a lesser extent 246-06. Notably, both of these mAbs also
recognize D325. It is of interest that the single site substitution
of arginine for Lys343 in rat SP-D confers binding to these
antibodies. Changes in other residues that interact with R343
based on structural analysis (e.g., E333) also cause loss of
binding of 246-05 and reduction of binding to 246-06, sug-
gesting that the orientation of R343 is altered in these mutants.
mAbs detect structural changes in NCRD that correlate with
loss of antiviral activity. mAbs can readily detect major struc-
tural changes in NCRD as illustrated by the case of hW340F.
W340 is a highly conserved residue in the core of the NCRD
and more generally in C-type lectins. Even the seemingly
conservative substitution of phenylalanine led to loss of anti-
viral activity with altered binding of nearly all tested antibod-
ies; this is despite retention of normal intrachain disulfide bond
formation of the CRD (data not shown). The fact that hW340F
even caused loss of the highly conserved 246-08 and 246-04
epitopes suggests major structural alteration in the CRD.
Arg349 plays an important role in tethering Arg343 in
position, as does Glu333, but substitution of the latter residue
with alanine causes more extensive changes. This probably
reflects important interactions of this residue with Asn341,
which coordinates with calcium at the primary carbohydrate
binding site. As noted, the hE333A mutant loses all antiviral
activity, whereas hR349A has a much smaller but significant
reduction in activity.
The hF335A substitution also markedly changes structure
and leads to a loss of antiviral activity; however, the conser-
vative mutations hF335Y and hF335W did not similarly alter
structure and were associated with a statistically significant
increase in neutralizing activity. We (3) have shown that F335
forms part of an extended binding surface (i.e., by forming a
secondary binding site for the 3rd hexose ring in maltotriose
and probably other ligands). Our findings suggest that the
aromatic residue in this position is important for viral binding.
It is unclear at this point why the hF335A, hNNK, and hW340F
mutant NCRDs actually promoted viral infectivity, and this
will be investigated in future studies.
Characterization of an extended binding site for IAV. Figure 8
depicts the ligand binding surface of the SP-D NCRD trimer,
indicating key amino acids mutated for this study. Based on
findings presented in this and previous papers, the ridges on
either side of the saccharide binding site of SP-D are involved
in viral recognition and antiviral activity. These ridges are
made up principally by the hydrophilic residues D325 and
R343 (yellow and blue in Fig. 8). The effect of R343 on viral
binding is particularly evident, since hydrophobic substitutions
in this area markedly increase viral binding and antiviral
activity. In contrast, replacing R343 with another basic residue
(lysine) does not significantly alter antiviral activity (despite
significantly increasing binding to LPS and PI). The conserva-
tive substitution, D325N, does not alter antiviral activity, but a
RAK insertion in that area does. Studies of other substitutions
for D325 are underway. Note that D324 is not located on the
binding surface but rather on the side surface of the NCRD.
This may explain why alteration of this residue did not alter
antibody binding or antiviral activity. The approximate loca-
tions of antibody binding sites are also indicated in Fig. 8.
In this paper, we demonstrate that multiple additional resi-
dues on the NCRD surface contribute to antiviral activity. F335
(shown in green in Fig. 8) contributes since the F335Y and
F335W increase viral neutralizing activity slightly, whereas the
F335A substitution ablates viral inhibition. It is possible that
the conservative substitutions increase stacking interactions
with viral oligosaccharides (note that the 3rd ring in maltotri-
ose overlies and has binding interactions with F335; see Fig. 8)
(3). The F335A substitution, in contrast, may decrease viral
binding by either eliminating stacking interactions or by caus-
ing more extensive alterations in the surrounding NCRD struc-
ture (as suggested by alterations in binding of several mAbs).
Some of the charged residues on the NCRD surface also
affect viral interactions (Fig. 8), including E333 (orange), E347
(cyan), R349 (magenta), and K348. Substitutions at K348
slightly increased antiviral activity, whereas the R349A and
E347A substitutions slightly reduced, and the E333A substitu-
tion eliminated, antiviral activity. Antiviral activity can be
further increased by cross-linking of NCRDs through mAbs
that bind to other areas on the CRD that have yet to be defined.
Overall, the colored portions of the binding surface of the
human SP-D NCRD define an extended area that is involved in
binding of blocking mAbs and viral binding. It should be noted
that the effects of mutating some of these residues could relate
to structural changes in surrounding residues as well as (or
Fig. 8. Diagram of the extended binding surface of human SP-D NCRD. The figure was rendered in PovRay from DeepView. The figure shows the molecular
surface of the SP-D-maltotriose complex [Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB) code 2GGU]. The ligand is shown in
stick figure. In A, the approximate sites for antibodies 246-02 (red), 246-03 (orange), and 246-07 (green) are shown on different heads of the trimer. In B, the
sites for antibodies 246-05 (cyan) and 246-06 (blue) are shown. The bottom monomer in B shows the contribution to the molecular surface from the key residues
Glu321 (red), Asp325 (yellow), Glu333 (orange), Phe335 (green), Arg343 (blue), E347 (cyan), and Arg349 (magenta). The orientation of the figure is looking
down from above on the planar binding surface of the trimer.
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instead of) direct interaction of the mutated residues with
ligands. For instance, the E333A, E347A, and R349A substi-
tutions might affect the orientation of R343V or calcium
chelating residues. The F335A mutation appears to cause a
major change in NCRD structure. W340 is clearly very impor-
tant for the overall structure of the NCRD, and this probably
explains the loss of antiviral activity of W340F.
Summary. The mAbs used in this study all have distinct
epitopes on the hNCRD and are, therefore, useful in comparing
mechanisms of binding to specific ligands. We provide evi-
dence for partially distinct mechanisms of binding of hNCRD
to gp-340, IAV, and mannan. The mAbs also proved useful in
monitoring structural changes resulting from mutation of key
residues in the CRD (e.g., R343 or F335). Through correlation
of mutational and antibody recognition analysis with crystal-
lographic findings and antiviral activity, we develop a detailed
picture of the surface features of the SP-D CRD involved in
viral binding and inhibition. The analysis reveals, for the first
time, an extended binding site for IAV; calcium-dependent
antiviral activity involves residues flanking the primary carbo-
hydrate binding site as well as more remote residues on the
ligand binding interface.
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